Previous close | 866.80 |
Open | 874.50 |
Bid | 884.10 x 0 |
Ask | 886.60 x 0 |
Day's range | 867.30 - 886.60 |
52-week range | 504.40 - 932.00 |
Volume | |
Avg. volume | 2,744,119 |
Market cap | 3.955T |
Beta (5Y monthly) | 0.19 |
PE ratio (TTM) | 47.62 |
EPS (TTM) | 18.62 |
Earnings date | 02 May 2024 |
Forward dividend & yield | 12.80 (1.44%) |
Ex-dividend date | 22 Mar 2024 |
1y target est | 905.68 |
Earnings preview of key companies reporting next week and what to look out for.
Bagsværd, Denmark, 26 April 2024 – In accordance with Section 32 of the Danish Capital Markets Act, Novo Nordisk A/S is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred. Referring to Company Announcement no 32/2024 dated 24 April 2024, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk A/S as per 26 April 2024. Number of
Eli Lilly, Novo Nordisk, Merck and AbbVie are part of the Zacks Industry Outlook article.